FDA Approves New Lung Cancer Therapy
The FDA has given accelerated approval to a drug – sotorasib – as a therapy for non-small cell lung cancer (NSCLC) that has KRAS G12C mutations. NSCLC is the most common type of lung cancer, and constitutes about 85% of all lung cancers. This is the form of lung cancer most associated with a history of […]
